LON:GNS Genus (GNS) Share Price, News & Analysis GBX 2,605 -35.00 (-1.33%) As of 08/29/2025 12:14 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesBuy This Stock About Genus Stock (LON:GNS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genus alerts:Sign Up Key Stats Today's Range 2,600▼ 2,65550-Day Range 1,924▼ 2,71552-Week Range 1,424▼ 2,760Volume92,052 shsAverage Volume222,540 shsMarket Capitalization£1.71 billionP/E RatioN/ADividend Yield0.01%Price TargetGBX 2,725Consensus RatingBuy Company Overview Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom. Read More Genus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreGNS MarketRank™: Genus scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingGenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenus has only been the subject of 2 research reports in the past 90 days.Read more about Genus' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genus is -42,016.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genus is -42,016.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioGenus has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenus has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GNS. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldGenus pays a meaningful dividend of 1.21%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGenus does not have a long track record of dividend growth.Read more about Genus' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for GNS. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 5 people have searched for GNS on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.59% of the stock of Genus is held by insiders.Percentage Held by Institutions63.38% of the stock of Genus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Genus' insider trading history. Receive GNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNS Stock News HeadlinesGenus (LON:GNS) Price Target Raised to GBX 2,900 at Shore CapitalAugust 22, 2025 | americanbankingnews.comThose who invested in Genus (LON:GNS) a year ago are up 50%July 23, 2025 | uk.finance.yahoo.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).August 31 at 2:00 AM | Weiss Ratings (Ad)1 stock from the FTSE 250 that could be set for a big turnaroundJuly 1, 2025 | msn.comGenus Stock Price HistoryJune 10, 2025 | investing.comInstitutional investors in Genus plc (LON:GNS) lost 3.3% last week but have reaped the benefits of longer-term growthMay 26, 2025 | finance.yahoo.comUK shares advance as investors react to wave of corporate earningsApril 30, 2025 | msn.comGenus rockets 27% in the FTSE 250! Should I buy this UK stock?April 30, 2025 | msn.comSee More Headlines GNS Stock Analysis - Frequently Asked Questions How have GNS shares performed this year? Genus' stock was trading at GBX 1,550 at the beginning of the year. Since then, GNS stock has increased by 68.1% and is now trading at GBX 2,605. How were Genus' earnings last quarter? Genus plc (LON:GNS) posted its quarterly earnings data on Thursday, February, 27th. The company reported $39.80 EPS for the quarter. Genus had a net margin of 1.18% and a trailing twelve-month return on equity of 1.41%. Read the conference call transcript. How do I buy shares of Genus? Shares of GNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Genus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genus investors own include Meta Platforms (META), Lloyds Banking Group (LLOY), Rolls-Royce Holdings plc (RR.L), AstraZeneca (AZN), Barclays (BARC), BP (BP) and Clinigen Group (CLIN). Company Calendar Last Earnings2/27/2025Today8/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPersonal Services Current SymbolLON:GNS CIKN/A Webwww.genusplc.com Phone+44-1256-347100FaxN/AEmployees480Year FoundedN/APrice Target and Rating Average Price Target for GenusGBX 2,725 High Price TargetGBX 2,900 Low Price TargetGBX 2,550 Potential Upside/Downside+4.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX (0.06) Trailing P/E RatioN/A Forward P/E Ratio36.71 P/E Growth2.87Net Income£7.87 million Net Margins1.18% Pretax MarginN/A Return on Equity1.41% Return on Assets3.31% Debt Debt-to-Equity Ratio53.12 Current Ratio1.80 Quick Ratio1.08 Sales & Book Value Annual Sales£671.60 million Price / Sales2.55 Cash FlowGBX 51.52 per share Price / Cash Flow50.56 Book ValueGBX 827.95 per share Price / Book3.15Miscellaneous Outstanding Shares65,693,000Free FloatN/AMarket Cap£1.71 billion OptionableNot Optionable Beta0.37 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (LON:GNS) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genus plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Genus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.